* Viracta Therapeutics Inc VIRX.OQ reported a quarterly
adjusted
loss of 25 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -32 cents. The mean expectation of
three analysts for the quarter was for a loss of 37 cents per
share. Wall Street expected results to range from -40 cents
to -34 cents per share.
* Reported revenue was zero; analysts expected zero.
* Viracta Therapeutics Inc's reported EPS for the quarter
was a
loss of 25 cents.
* The company reported a quarterly loss of $9.83 million.
* Viracta Therapeutics Inc shares had fallen by 14.4% this
quarter and lost 18.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 18.4%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $5.00
This summary was machine generated from LSEG data August 14 at
01:12 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.37 -0.25 Beat
Mar. 31 2024 -0.35 -0.23 Beat
Dec. 31 2023 -0.31 -0.35 Missed
Sep. 30 2023 -0.30 -0.33 Missed